SURVYR

GENB

Generate Biomedicines, Inc.
$15.38
+$2.17 (16.43%)Oct 28 close
Healthcare CompareTechnicals
-13%+5%+24%+43%+61%Feb 2026Oct 2026Jun 202652w low $11.00
GENBSPY
Wall St. Highest PT $30.00 (+95.1%) Wall St. Avg PT $27.00 (+75.6%)
$11$16$21$26$31POC $13Hi $30Avg $27
Underwater Drawdown %Max DD -40.7%Current -24.5%
0.0%-40.7%
Relative Strength vs SPY+8.1% vs SPYOutperforming
+56%0%-56%
1W
+$2.27 (17.32%)
1M
+$0.47 (3.15%)
3M
+$2.30 (17.58%)
6M
+$3.00 (24.23%)
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
5 analysts · mean score 1.33
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$15.38
Average target$27.00
+$11.62 (+75.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$22.00
Median$27.00
High$30.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-05 · HC Wainwright & Co. reiterated Buy on GENB
Reiterated
2026-09-08 · HC Wainwright & Co. reiterated Buy on GENB
Reiterated
2026-08-28 · HC Wainwright & Co. reiterated Buy on GENB
Reiterated
2026-05-14 · Morgan Stanley reiterated Overweight on GENB
Reiterated
2026-05-08 · HC Wainwright & Co. reiterated Buy on GENB
Initiated
2026-04-13 · HC Wainwright & Co. started covering GENB at Buy

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.7B
P/E (next 12 months, estimated)-5.8
52-week range$11.00 – $22.67
Revenue growth (latest quarter vs a year ago)-37.7%
Dividend yieldNo dividend
Analyst consensusStrong Buy (5)
Average analyst price target$27.00 (+76%)

What they do

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for GENB yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
SURVYR. Long Book
Not in the current book

Earnings & events

GENB earningsNext report in 8 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$0.55 range -$0.67–-$0.44
Revenue consensus$7.8M 5 analysts
Last 2 quarters · EPS vs estimate
Aug 6, 2026-$0.52est -$0.49−5.6%Below estimates
May 7, 2026-$1.07est -$0.51−111.2%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:14:23 ET
26-0526-08-1.070.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$6.3M–
2026-03-31$7.2M–
2025-06-30$10.1M–
2025-03-31$8.8M–

News & catalysts

More news
Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
Pharmaceutical Technology · Oct 14
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Benzinga · Oct 14
Generate Biomedicines, Zealand Pharma Report Partnership
MT Newswires · Oct 13
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
GlobeNewswire · Oct 13
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
GlobeNewswire · Oct 13
Rating changes
Reiterated
2026-10-05 · HC Wainwright & Co. reiterated Buy on GENB
Reiterated
2026-09-08 · HC Wainwright & Co. reiterated Buy on GENB
Reiterated
2026-08-28 · HC Wainwright & Co. reiterated Buy on GENB
Reiterated
2026-05-14 · Morgan Stanley reiterated Overweight on GENB
Reiterated
2026-05-08 · HC Wainwright & Co. reiterated Buy on GENB
Initiated
2026-04-13 · HC Wainwright & Co. started covering GENB at Buy

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Arnold Frances
Director · 2026-09-01
Sell
$16.0K

Stats refreshed 2026-10-21 18:14:23 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

Coteau 0.9 · Oct 21, 2026